University of California

Elizabeth M Boon

Michael A Marletta

Stephen P L Cary

Jonathan A Winger

Emily Weinert

Stephen Pl Cary

Stephen P Cary

Stephen PL Cary

H&#x2014;NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas Odelivery. The engineered H&#x2014;NOX proteins comprise mutations that impart altered Oor NO ligand-binding relative to the corresponding wild-type H&#x2014;NOX domain, and are operative as physiologically compatible mammalian blood Ogas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H&#x2014;NOX proteins for the treatment of any condition for which delivery of Ois beneficial.

Compositions and methods for the delivery of oxygen

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or Oligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.

Compositions and methods for the delivery of nitric oxide

H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas Odelivery. The engineered H-NOX proteins comprise mutations that impart altered Oor NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood Ogas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of Ois beneficial.

Growing community of inventors

Stony Brook, NY, United States of America

Elizabeth M Boon